1 / 6

Ulcerative Colitis Market Expected to Reach $4,785 Million by 2023

global ulcerative colitis market was valued at $4,785 million in 2016, and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023. The mild ulcerative colitis disease type accounted for nearly half of the market share in 2016.

newmarketindustry
Télécharger la présentation

Ulcerative Colitis Market Expected to Reach $4,785 Million by 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ulcerative Colitis Market

  2. Advancements in ulcerative colitis treatment modalities has led to the emergence of biologics such as tumor necrosis factors (TNF) in developing drugs. This has led to the shift from traditional therapies towards engineered drugs that has also enhanced the efficacy rate of drugs. Ulcerative Colitis Market was valued at $4,785 million in 2016, and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023. The mild ulcerative colitis disease type accounted for nearly half of the market share in 2016. Get Sample Report

  3. Ulcerative colitis is an inflammatory bowel disease that affects the colon and rectum of the human body. The disease affects people of any age and most commonly it begins during adolescence and early adulthood, but it may also occur later in life. Ulcerative colitis is highly prevalent in the U.S., England, and northern Europe. The most commonly preferred treatment options for ulcerative colitis are traditional medications made of biologics and small molecules.

  4. The prime factors factor that drive global ulcerative colitis market are increase in prevalence of ulcerative colitis globally and rise in R&D activities by key players towards new drug formulations for disease treatment. In addition, increase in patient assistance programs that has raised the demand for branded drugs further fuels the market growth. Untapped emerging economies that lack proper medical assistance are expected to provide numerous opportunities for market expansion. The oral segment dominated the ulcerative colitis market with half of the market share in 2016, as it is an easy route of administration and immediate destruction of drugs by gastric acid is avoided. The injectable segment is expected to register the highest CAGR of 6.9%.

  5. Key Findings of the Ulcerative Colitis Market: • The severe disease type segment is anticipated to grow with a CAGR of 6.7% from 2017 to 2023. • U.S. was the highest shareholder in the North American ulcerative colitis market in 2016, and is poised to retain its lead during the forecast period. • Biologics registered the highest CAGR of 6.9%. • India is expected to grow at a significant rate of 7.1%. • The small molecules segment accounted for half of the share in 2016, registering a CAGR of 6.1%.

  6. The key players operating in the global ulcerative colitis market are Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Co., Sanofi Aventis A/S, AstraZeneca plc, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., and Abbott Laboratories. The other prominent players in the value chain include Avaxia Biologics Inc., BioLineRx Ltd., Celgene Corporation, Mitsubishi Tanabe Pharma Corporation, and Salix Pharmaceuticals, Inc.

More Related